Related Experiment Video
Updated: Feb 27, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
12.9K
Ocrelizumab: a B-cell depleting therapy for multiple sclerosis
Dejan Jakimovski1, Bianca Weinstock-Guttman2, Murali Ramanathan3
1a Buffalo Neuroimaging Analysis Center, Department of Neurology , Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York , Buffalo , NY , USA.
Expert Opinion on Biological Therapy
|June 30, 2017
Summary
B lymphocyte depletion therapy shows promise for multiple sclerosis (MS) patients, offering a new treatment option. While effective, long-term consequences require further monitoring and awareness for managing MS progression.
Area of Science:
- Neuroimmunology
- Neurology
- Immunopathology
Background:
- Multiple sclerosis (MS) is a leading cause of neurological disability in young adults.
- Disease-modifying therapies have improved outcomes, but significant disability progression persists in some patients.
- B-cells are increasingly recognized for their role in MS pathogenesis.
Purpose of the Study:
- To review the immunopathology of B-cells in MS.
- To evaluate B-cell depletion therapy, specifically ocrelizumab, as a therapeutic target.
- To analyze the efficacy, safety, and tolerability of ocrelizumab in recent clinical trials.
Main Methods:
- Review of immunopathology literature concerning B-cells in MS.
- Analysis of data from published ocrelizumab Phase III clinical trials.
- Synthesis of current understanding of B-cell targeted therapies for MS.
Main Results:
- B-cell depletion therapy presents a promising therapeutic strategy for MS.
- Ocrelizumab demonstrated efficacy in Phase III trials, impacting disease progression.
- Safety and tolerability profiles of ocrelizumab were evaluated.
Conclusions:
- B lymphocyte depletion offers a compelling new treatment avenue for multiple sclerosis.
- Continued vigilance is necessary to identify potential unknown long-term effects.
- Further research and monitoring are essential for optimizing B-cell targeted MS therapies.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
658
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
658
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
577
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
577
01:27Cytotoxic T Cells-mediated Immune Response
7.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.7K
01:24B Cell Activation and Differentiation
17.4K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.4K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577